Article Details

Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors | Seeking Alpha

Retrieved on: 2022-04-18 20:26:16

Tags for this article:

Click the tags to see associated articles and topics

Kinnate Biopharma begins dosing in phase 1 trial of KIN-3248 in advanced tumors | Seeking Alpha. View article details on hiswai:

Excerpt

Kinnate Biopharma (KNTE) said the first patient began treatment in a phase 1 trial of KIN-3248 in adults with advanced tumors harboring FGFR2 ...

Article found on: seekingalpha.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up